Abstract
In 2006, the US urological device market was valued at over $1.7 billion.
This market is comprised of revenue from urinary incontinence, stone
management, benign prostatic hyperplasia, prostate cancer, urological
endoscopes, erectile dysfunction, ureteral access and nephrostomy.